Fight like Cal Ripken Jr.
Cal Ripken, Jr. is a prostate cancer survivor. Although he did not present with traditional signs and symptoms, he went to his urologist to be checked out. With a normal but slightly rising PSA level over the course of several years, there was not a clear reason to go to biopsy. However, his physician introduced the ExoDx Prostate Test because he fit the intended use: age 50+ years, PSA level 2-10ng/mL, and considering an initial prostate biopsy.
The EPI test is a simple, non-invasive urine test that helps inform the prostate biopsy decision. A score below the cut-point of 15.6 informs a reduced risk of finding high-grade prostate cancer (defined as < Gleason 7) and a decision can be made to defer a prostate biopsy safely, with a high degree of confidence. A score above the cut-point of 15.6 informs a greater risk of finding high grade prostate cancer (defined as ≥ Gleason 7) and a decision can be made to proceed to biopsy.